

Connecticut HB 6669

Cystaran® (Cysteamine)

Leadiant Biosciences, Inc. (“Leadiant”) provides the following information to Connecticut prescribers, as required by Connecticut House Bill 6669.

The pricing information below reflects Leadiant’s Wholesale Acquisition Costs (“WAC”) for their product: **Cystaran®**. The WAC represents published catalogue or list price and may not represent actual transactional prices.

The price a customer pays may vary from the prices listed, depending, for example, on how the customer purchases the product, the availability of discounts, the wholesaler/distributor, or other charges.

WAC for Cystaran®

PRODUCT	NDC	DOSAGE FORM AND STRENGTH	WHOLESALE ACQUISITION COST (WAC)
Cystaran®	54482-0035-02	Ophthalmic Solution 0.44 %	\$2,856.70

Drug in the same therapeutic class as **Cystaran®** include:

PRODUCT	NDC	DOSAGE FORM AND STRENGTH	WHOLESALE ACQUISITION COST (WAC)
Cystadrops	55292-0410-05	Ophthalmic Solution 0.37%	\$2,654.99

For more information on the price disclosure requirements, please contact the Colorado State Board of Pharmacy at:

State Board of Pharmacy
450 Columbus Blvd.

Hartford, CT 06103

Ph. (860) 713-6070 | Fax: (860) 706-1242 | Website: <https://portal.ct.gov/DCP/Drug-Control-Division/Commission-of-Pharmacy/The-Commission-of-Pharmacy>

Cystaran® is a registered trademark of Leadiant.

Copyright© 2026 Leadiant All rights reserved.

07/10/2026